The impact of COVID-19 pandemic on outcomes of women with breast cancer recurrence

Author:

Mühlmann Lindson1,Pimentel Franklin Fernandes1,Tiezzi Daniel Guimarães1,Carrara Hélio Humberto Angotti1,de Andrade Jurandyr Moreira1,Reis Francisco Jose Candido dos2ORCID

Affiliation:

1. Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto: Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto

2. Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto

Abstract

Abstract Purpose The COVID-19 pandemic has impacted the management of several diseases. Our goal was to assess the outcomes of women diagnosed with relapsed breast cancer during the pandemic period. Methods We evaluated a cohort of 187 women with breast cancer recurrence out of a total of 2,891 patients diagnosed with breast cancer between January 2011 and March 2022. Results At the time of recurrence diagnosis, 116 patients (62%) had distant metastasis and 71 (38%) had local recurrence. Of the women with initial local recurrence, 28% (35) died, while 72% (91) of the women with distant recurrence died. The pandemic group showed a significant decrease in overall survival (OS) compared to the pre-pandemic group (median 9 months versus 22 months, respectively; HR: 1.92; 95% CI: 1.19–3.12). Conclusion The pandemic had a negative impact on the survival of patients with breast cancer recurrence.

Publisher

Research Square Platform LLC

Reference17 articles.

1. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou F;Lancet,2020

2. COVID-19: towards controlling of a pandemic;Bedford J;Lancet,2020

3. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China;Liang W;Lancet Oncol,2020

4. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay J;Int J Cancer,2019

5. Instituto Nacional do Câncer (2019) Estimativa 2020: incidência do Câncer no Brasil. https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf. Accessed 20 Oct 2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3